Patient-Data-Free BVCTs Eliminate PFS-OS Discordance Before Decisions
BVCT locked No. 1195 on tovecimig in COMPANION-002 on : PFS superior to paclitaxel alone, OS benefit depending on DLL4 expression. The readout showed superior PFS and non-superior OS, 540 days after the lock; the dashboard classifies it True Negative (TN). Nine further PFS/OS calls are listed below.
BVCT 1195 validated by COMPANION-002. Decisive clinical validation.
Following the COMPANION-002 phase 2/3 readout on (here) — superior to SoC (paclitaxel alone) in PFS, non-superior to SoC in OS — BioinvestGPT’s ex-ante prediction of PFS–OS discordance, shared with Big Pharma in the data room about 18 months earlier, turns out to be spot-on (see No. 1195, COMPANION-002, on the dashboard).
In this case, the intra-tumoral DLL4 expression level is a crucial OS differentiator that must be used to stratify patients to achieve superior-to-SoC OS benefit.
The record. No. 1195 was locked on , 540 days before the readout. Recorded technical call: SUCCESS (statistically significant additive clinical benefit in ORR/PFS superior to paclitaxel monotherapy regardless of DLL4 baseline expression). Recorded commercial call: partial SUCCESS (commercially sufficient additive clinical benefit in OS superior to paclitaxel monotherapy for high-DLL4-baseline-expression patients) partial FAILURE (commercially insufficient additive clinical benefit in OS non-superior to paclitaxel monotherapy for low-DLL4-baseline-expression patients). The dashboard classifies the readout as True Negative (TN).
RWD lacks clinical foresight; BVCT has clinical foresight.
Real-World Ex-Ante Validations.
This adds to BVCT’s real-world ex-ante validations of its remarkable reliability — 674 of 705 scored predictions correct in the cohort frozen on 24 Sep 2026 — including ten ex-ante calls on the well-known but difficult discordance between PFS HR vs. SoC and OS HR vs. SoC (each card below shows its classification), using drug design only, in a fully patient-data-free manner. Visit data.bioinvestgpt.com for more information.
The ten calls on the carousel, as recorded on the dashboard
SUCCESS (statistically significant additive clinical benefit in ORR/PFS superior to paclitaxel monotherapy regardless of DLL4 baseline expression)
Commercial Prediction
partial SUCCESS (commercially sufficient additive clinical benefit in OS superior to paclitaxel monotherapy for high-DLL4-baseline-expression patients) partial FAILURE (commercially insufficient additive clinical benefit in OS non-superior to paclitaxel monotherapy for low-DLL4-baseline-expression patients)
partial SUCCESS (statistically maybe significant yet weak additive clinical benefit in ORR/PFS non-superior to carboplatin + pemetrexed combotherapy)
Commercial Prediction
partial SUCCESS (commercially maybe sufficient yet moderate additive clinical benefit in OS numerically superior to carboplatin + pemetrexed combotherapy)
Ivonescimab · Summit Therapeutics, under licence from Akeso · EGFR-mutant NSCLC.
partial SUCCESS (statistically significant additive clinical benefit in PFS superior to daratumumab when combined with bortezomib + dexamethasone) partial FAILURE (statistically insignificant additive clinical benefit in ORR non-superior to daratumumab)
Commercial Prediction
FAILURE (commercially insufficient additive clinical benefit in OS non-superior to daratumumab when combined with bortezomib + dexamethasone)
partial SUCCESS (statistically significant additive clinical benefit in PFS superior to bortezomib when combined with pomalidomide + dexamethasone) partial FAILURE (statistically insignificant additive clinical benefit in ORR non-superior to bortezomib)
Commercial Prediction
FAILURE (commercially insufficient additive clinical benefit in OS non-superior to bortezomib when combined with pomalidomide + dexamethasone)
partial SUCCESS (statistically significant (additive) clinical benefit in ORR/PFS numerically superior to cetuximab yet inferior to petosemtamab as monotherapy or in combination with pembrolizumab)
Commercial Prediction
FAILURE (commercially insufficient (additive) clinical benefit in OS inferior to chemotherapy/cetuximab/petosemtamab as monotherapy or in combination with pembrolizumab)
Ficerafusp alfa · Bicara Therapeutics · EGFR-driven solid tumours (Phase 1; listed on the carousel by index only).
partial SUCCESS (statistically maybe significant yet weak clinical benefit in ORR/PFS numerically superior to chemotherapy yet numerically inferior to BL-B01D1); partial FAILURE (statistically insignificant clinical benefit in tolerability inferior to chemotherapy yet numerically superior to BL-B01D1)
Commercial Prediction
FAILURE (commercially insufficient clinical benefit in OS inferior to chemotherapy yet numerically superior to BL-B01D1)
Patritumab deruxtecan · Daiichi Sankyo / Merck & Co. · EGFR-mutant NSCLC (listed on the carousel by index only). Counted to the second readout; the first readout, , reported PFS with OS not yet mature.
partial SUCCESS (statistically significant yet moderate additive clinical benefit in ORR/PFS for gedatolisib + fulvestrant + palbociclib moderately superior to SoC alpelisib + fulvestrant for PIK3CA MT population slightly superior to SoC fulvestrant for PIK3CA WT population despite with additional gedatolisib-related toxicity) partial FAILURE (statistically insignificant additive clinical benefit in ORR/PFS for gedatolisib + fulvestrant non-superior to SoC fulvestrant for both PIK3CA MT population and PIK3CA WT with additional gedatolisib-related toxicity)
Commercial Prediction
partial FAILURE (commercially insufficient additive clinical benefit in OS for gedatolisib + fulvestrant + palbociclib at most numerically superior to SoC alpelisib + fulvestrant for PIK3CA MT population and non-superior to SoC fulvestrant for PIK3CA WT population despite with additional gedatolisib-related toxicity) FAILURE (commercially insufficient additive clinical benefit in OS for gedatolisib + fulvestrant non-inferior to SoC for both PIK3CA MT population PIK3CA WT population with additional gedatolisib-related toxicity)
Gedatolisib · Celcuity · HR+/HER2− breast cancer (listed on the carousel by index only).
Earlier Decisions, Same Certainty.
More remarkably, BVCT’s clinical foresight has now expanded to reliably cover earlier decision steps (bvct.bioinvestgpt.com):
Evaluate to what extent a BIC drug design could achieve clinical superiority over blockbuster SoC — in 7 days.
Assess to what extent an FIC drug target could clinically outperform blockbuster SoC — in 7 days.
BeatSoC-Oriented Drug Discovery.
In parallel, BVCT’s clinical foresight has also expanded into BeatSoC-oriented drug discovery:
Asset A. An FIC oncology small molecule we have discovered that could achieve tissue-agnostic OS HR < 0.6 vs. SoC.
Asset B. An FIC oncology ADC (novel antibody target + novel non-cytotoxic payload) we have discovered that could achieve tissue-agnostic OS HR < 0.6 vs. SoC in synergy with Asset A.
Big Pharma’s Strategic Position.
Big Pharma is in the best strategic position to fully unleash the value of the full BVCT capacities — especially where patients cannot afford slow, trial-and-error R&D cycles.
Patient-data-free causal BVCTs have achieved a level of versatility, maturity, and capital efficiency that probably remains permanently — structurally — out of reach for data-driven statistical LLMs, due to their dependence on historical data and inherent limitations in complex causal simulation.
Let’s Move — End-to-End.
Let’s start an end-to-end partnership to position Big Pharma with a decisive competitive advantage — analogous to SpaceX’s dominance in aerospace — while, in our view, others allocate billion-dollar capital, drawn from tightened revenues, into LLMs for marginal returns.